Siegfried Holding AG, headquartered in Zofingen, Switzerland, today announced that it will propose Isabelle Welton for election to the Board of Directors on the occasion of its General Meeting of Shareholders on 17 April 2020.
Isabelle Welton (1963) looks back on a successful career in international companies in the financial services and IT industries. She started her career with Citibank in Tokyo and subsequently changed to IBM, where she held various positions in marketing and communications before being appointed country general manager of IBM in Switzerland. In 2013, Isabelle Welton joined Zurich Insurance Group as member of the Group Executive Board with responsibility for Human Resources & Corporate Culture. Today, she is the owner of a consulting company focusing on corporate culture and change processes. Isabelle Welton serves on the board of NZZ Media Group, Avobis Group and on the foundation boards of Swisscontact, SOS Children’s Village Switzerland and Lucerne Festival. Isabelle Welton is a Swiss citizen.
Dr. Rudolf Hanko, who headed the company as CEO from 2009 to the end of 2018, will not stand for reelection. Dr. Andreas Casutt (Chairman), Ulla Schmidt, Colin Bond, Prof. Dr. Wolfram Carius, Reto Garzetti and Dr. Martin Schmid are standing for reelection.
Andreas Casutt: "As an entrepreneur with extensive management experience, Isabelle Welton will strengthen our Board of Directors. She is well versed in sectors of great relevance to Siegfried today and in the future. Rudolf Hanko will retire as a member of the Board of Directors after successfully handing over his responsibilities as CEO to his successor, Wolfgang Wienand. Siegfried developed into the company it is today under the leadership of Rudolf Hanko and owes him a great deal of gratitude.”
Peter A. Gehler, Chief Communications Officer
Tel. +41 62 746 11 48
Mobile +41 79 416 41 16
Siegfried Holding AG
Untere Bruehlstrasse 4
Tel. +41 62 746 11 11
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. At the end of 2018, Siegfried reported annual sales of CHF 794.3 million and employs at the time being approximately 2350 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including aseptic filling.
Cautionary Statements Regarding Forward-Looking Statements
This press release may contain forward-looking statements based on current assumptions and forecasts made by Siegfried Group management and other information currently available to the Siegfried Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Siegfried Holding AG does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to conform them to future events or developments.